Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for Ang-2 in plaque stability. Despite the availability of Ang-2 blocking agents, their clinical use is still lacking. Our aim was to establish if Ang-2 has a role in atheroma development and in the transition of subclinical to clinically relevant atherosclerosis. We investigated the effect of antibody-mediated Ang-2 blockage on atherogenesis after in a mouse model of atherosclerosis. METHODS: Hypercholesterolemic (low-density lipoprotein receptor(-/-) apolipoprotein B(100/100)) mice were subjected to high-cholesterol diet for eight weeks, one group with and one group without Ang-2 blocking antibody treatment during weeks 4-8.To enhance plaque development, a peri-adventitial collar was placed around the carotid arteries at the start of antibody treatment. Aortic root, carotid arteries and brachiocephalic arteries were analyzed to evaluate the effect of Ang-2 blockage on atherosclerotic plaque size and stable plaque characteristics. RESULTS: Anti-Ang-2 treatment reduced the size of fatty streaks in the brachiocephalic artery (-72%, p < 0.05). In addition, antibody-mediated Ang-2 blockage reduced plasma triglycerides (-27%, p < 0.05). In contrast, Ang-2 blockage did not have any effect on the size or composition (collagen content, macrophage percentage, adventitial microvessel density) of pre-existing plaques in the aortic root or collar-induced plaques in the carotid artery. CONCLUSIONS: Ang-2 blockage was beneficial as it decreased fatty streak formation and plasma triglyceride levels, but had no adverse effect on pre-existing atherosclerosis in hypercholesterolemic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933 · cited 2×
“The therapeutic potential of Ang-2 blockage is based on the adverse effects of Ang-2 on processes leading to plaque instability: microvessel growth (angiogenesis), decreased pericyte coating of microvasculature and increased vascular permeability [2,13,14], that promotes leukocyte recruitment [13,15,16].”
BackgroundTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676 · cited 1×
“The therapeutic potential of Ang-2 blockage is based on the adverse effects of Ang-2 on processes leading to plaque instability: microvessel growth (angiogenesis), decreased pericyte coating of microvasculature and increased vascular permeability [2,13,14], that promotes leukocyte recruitment [13,15,16].”
BackgroundJørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-2
Murdoch, C., Tazzyman, S., Webster, S., & Lewis, C. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7405 · Cited by 318 · cited 1×
“In addition, Tie-2 expressing macrophages respond to Ang-2 by secreting TNFa [17], which can contribute to the inflammation in the vessel wall.”
BackgroundWang, L., Gill, R., Pedersen, T. L., Higgins, L. J., Newman, J. W., & Rutledge, J. C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m700505-jlr200 · Cited by 303
Endothelial destabilization by angiopoietin-2 via integrin β1 activation
Hakanpaa, L., Sipila, T., Leppanen, V.-M., Gautam, P., Nurmi, H., Jacquemet, G., Eklund, L., Ivaska, J., Alitalo, K., & Saharinen, P. (2015) · Nature Communications · doi:10.1038/ncomms6962 · Cited by 287 · cited 1×
“Ang-2 is known to induce endothelial destabilization and vascular permeability [36], thus suggesting a beneficial effect of Ang-2 blockage.”
BackgroundSelf-citationEffects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216
Self-citationKienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Angiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage
Benest, A. V., Kruse, K., Savant, S., Thomas, M., Laib, A. M., Loos, E. K., Fiedler, U., & Augustin, H. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070459 · Cited by 178
Cited by
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Self-citationAngiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Sedding, D. G., Boyle, E. C., Demandt, J. A. F., Sluimer, J. C., Dutzmann, J., Haverich, A., & Bauersachs, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00706 · Cited by 228
Self-citation
Metadata
- Authors
- Theelen, T. L., Lappalainen, J. P., Sluimer, J. C., Gurzeler, E., Cleutjens, J. P., Gijbels, M. J., Biessen, E. A. L., Daemen, M. J. A. P., Alitalo, K., & Ylä-Herttuala, S.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 241
- Issue
- 2
- Pages
- 297-304
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W1566234231
- Cited by
- 58
- References
- 12
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2015.05.018
- The paper
- Theelen, T. L., Lappalainen, J. P., Sluimer, J. C., Gurzeler, E., Cleutjens, J. P., Gijbels, M. J., Biessen, E. A. L., Daemen, M. J. A. P., Alitalo, K., & Ylä-Herttuala, S. (2015). Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2015.05.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.